Is MIRA good buy ?

**Conclusion: MIRA is a *high-risk / high-reward* speculative play rather than a classic “buy-and-hold” candidate.** 🚦📉 Its eye-catching pre-clinical data and strategic acquisitions create real upside, but the stock’s micro-cap status, negative fundamentals, and extreme volatility mean only investors with a high tolerance for swings—and a multi-year horizon—should consider a small position. 🧐🚀 --- ### 1. Price Action & Technical Pulse • Last trade: **$1.43**, sitting just above near-term support at **$1.25** and far below resistance at **$2.45**. • Momentum gauges are neutral-to-slightly-bearish: RSI **47.6** (no overbought/oversold), MACD **+0.04** (weak bullish crossover), and KDJ **6.6** (deeply oversold territory). • Short-term moving averages are drifting upward (e.g., 20-day MA **$1.38**), hinting at a potential bounce, yet the broader trend remains weak. |market_code|code|Ticker|Name|Date|Closing Price| |---|---|---|---|---|---| |186|MIRA|MIRA.O|MIRA|20251022|1.43| |market_code|code|Ticker|Name|Date|Support Level|Resistance Level| |---|---|---|---|---|---|---| |186|MIRA|MIRA.O|MIRA|20251022|1.2500|2.4500| |market_code|code|Ticker|Name|Date|Moving Average| |---|---|---|---|---|---| |186|MIRA|MIRA.O|MIRA|20251022|1.5600| |market_code|code|Ticker|Name|Date|Boll|RSI|KDJ|MACD| |---|---|---|---|---|---|---|---|---| |186|MIRA|MIRA.O|MIRA|20251022|1.3812|47.5556|6.5808|0.0360| **Takeaway:** Technicals flash “catch-up” potential, but without a decisive break above $1.50–$1.60, momentum traders may stay cautious. 📊🤔 --- ### 2. Fundamentals: Still in the Red | Metric | Latest | Comment | |--------|--------|---------| | P/E (TTM) | **-3.49** | Loss-making; not useful for valuation | | P/B | **47.52** | Deeply above industry norm (~37) – rich for a pre-revenue firm | | Cash (MRQ) | **$0.73 M** | Very limited war-chest for R&D | | Debt/Equity | **0.08** | Virtually debt-free, a plus | | R&D (Q2-25) | **$0.50 M** | Small spend relative to peers | |market_code|code|Ticker|Name|Date|Cash and Cash Equivalents YoY|Cash and Cash Equivalents| |---|---|---|---|---|---|---| |186|MIRA|MIRA.O|MIRA|2024 Q3|-29.374114952635587|4144560| |186|MIRA|MIRA.O|MIRA|2024 Q4|-38.44887829962677|2832931| |186|MIRA|MIRA.O|MIRA|2025 Q1|-65.81498259271487|1206285| |186|MIRA|MIRA.O|MIRA|2025 Q2|-74.13131542424856|730475| |market_code|code|Ticker|Name|Date|R&D Expenses|R&D Expenses YoY| |---|---|---|---|---|---|---| |186|MIRA|MIRA.O|MIRA|2024 Q3|1067396|5.136064740576724| |186|MIRA|MIRA.O|MIRA|2024 Q4|861441|122.52384900922964| |186|MIRA|MIRA.O|MIRA|2025 Q1|314404|-58.75457183487346| |186|MIRA|MIRA.O|MIRA|2025 Q2|496197|-19.24691844247488| |market_code|code|Ticker|Name|Date|P/E(TTM)|P/S|Price to Book Ratio| |---|---|---|---|---|---|---|---| |186|MIRA|MIRA.O|MIRA|20241022|-1.381936||7.697033393030809| |186|MIRA|MIRA.O|MIRA|20241023|-1.408259||7.843643552898062| |186|MIRA|MIRA.O|MIRA|20241024|-1.487227||8.283474032499822| |186|MIRA|MIRA.O|MIRA|20241025|-1.697807||9.45635531143785| |186|MIRA|MIRA.O|MIRA|20241028|-2.066324||11.508897549579398| |186|MIRA|MIRA.O|MIRA|20241029|-2.276905||12.681778828517427| |186|MIRA|MIRA.O|MIRA|20241030|-2.895486||16.127117585397883| |186|MIRA|MIRA.O|MIRA|20241031|-2.882325||16.053812505464254| |186|MIRA|MIRA.O|MIRA|20241101|-2.500647||13.92796518738908| |186|MIRA|MIRA.O|MIRA|20241104|-2.43484||13.561439787720948| |market_code|code|Ticker|Name|Date|Free Cash Flow|Free Cash Flow YoY| |---|---|---|---|---|---|---| |186|MIRA|MIRA.O|MIRA|2024 Q3|-3916052|60.60378822342547| |186|MIRA|MIRA.O|MIRA|2024 Q4|-5882506|54.643624546282496| |186|MIRA|MIRA.O|MIRA|2025 Q1|-1901|99.97161836812634| |186|MIRA|MIRA.O|MIRA|2025 Q2|-1750164|77.53615217509892| **Key Points:** 1. Negative earnings and a sky-high P/B suggest the market is pricing in future clinical success, not current profitability. 2. Tiny cash pile means any trial delays or dilutive financing could pressure the share price sharply. 💥💸 --- ### 3. Catalysts & Strategic Moves • **Mira-55** outperformed morphine in pain/inflammation models, supporting an upcoming IND for chronic inflammatory pain. • **Ketamir-2** Phase-1 data showed favorable safety for neuropathic pain and PTSD. • Acquisition of **SKNY Pharmaceuticals** adds SKNY-1 (obesity/smoking cessation) to the mix, diversifying pipeline. • Binance listing of the *tokenized* Mira Network (AI trust layer) could unlock a new narrative, though it is a separate entity. These catalysts provide a credible story but are **years away** from revenue generation. 📅✨ --- ### 4. Market Sentiment & Liquidity • Net fund flow on 22-Oct shows **-$7.3 K** outflow, signaling short-term profit-taking after the 60-70 % spike. • Shares traded **3.3 M** vs. a 20-day average of ~0.7 M, confirming elevated volatility. |market_code|code|Ticker|Name|Date|Net Fund Flow|Net Fund Flow (Block Order)| |---|---|---|---|---|---|---| |186|MIRA|MIRA.O|MIRA|20250106|-43253.6261|-38906.4724| |186|MIRA|MIRA.O|MIRA|20250107|123534.9501|133910.5316| |186|MIRA|MIRA.O|MIRA|20250108|-186107.4621|-185253.5157| |186|MIRA|MIRA.O|MIRA|20250110|-38239.8176|-36867.7527| |186|MIRA|MIRA.O|MIRA|20250113|-4299.8467|-1866.4449| |186|MIRA|MIRA.O|MIRA|20250114|-29197.1057|-28061.7568| |186|MIRA|MIRA.O|MIRA|20250115|-876.9801|2301.6713| |186|MIRA|MIRA.O|MIRA|20250116|1526.8747|3287.3655| |186|MIRA|MIRA.O|MIRA|20250117|15167.5616|12685.7873| |186|MIRA|MIRA.O|MIRA|20250121|-25170.5983|-11053.4686| --- ### 5. Risk Dashboard 1. **Micro-cap liquidity** – wide bid-ask spreads can amplify losses. 2. **Clinical execution risk** – failure in Phase-1/2 trials would likely crush the stock. 3. **Dilution threat** – minuscule cash reserves may force future equity raises. 4. **Regulatory surprises** – even positive data can face FDA hurdles. --- ### 6. Bottom Line & Actionable View • **Speculative Buy (Size Small):** For investors seeking biotech alpha and can stomach violent swings, a starter position below $1.50 could make sense, targeting a re-rating if Mira-55 or Ketamir-2 hits Phase-2. • **Wait-and-See:** If you prefer clearer fundamentals or lower volatility, monitor pipeline milestones without committing capital until cash-flow projections turn positive. Stay nimble, set stop-losses, and remember: in micro-caps, patience and position sizing matter more than optimism. Good luck and happy investing! 🍀📈